恩替卡韦抗病毒治疗4周HBV DNA载量可预测48周病毒学应答

Analysis on the efficacy and predictors of entecavir in patients with chronic hepatitis B

目的评价恩替卡韦抗病毒的疗效并分析其预测因素。方法 61例慢性乙型肝炎患者接受恩替卡韦抗病毒治疗48周,分别于基线、4、12、24和48周检测患者肝功能、HBV血清标志物、HBV DNA定量。结果治疗48周时ALT复常率和HBV DNA转阴率分别达95.1%和91.8%,HBsAg定量较基线显著下降(P<0.05);48周时完全病毒学应答率与第4周时HBV DNA载量有显著相关性。结论恩替卡韦抗病毒安全、有效;第4周时HBV DNA载量对48周时完全病毒学应答率有很好的预测作用。

Objective To evaluate the antiviral efficacy of entecavir and to analyze relevant predictive factors. Methods Sixty-one patients with CHB were enrolled and given entecavir for 48 weeks. ALT,serological indicators and HBV DNA were determined at baseline,4^th week,12^th week,24^th week and 48^th week during the treatment. Results At 48^th week,rate of ALT normalization was 95. 1%,while rate of undetectable HBV DNA was 91. 8% and HBsAg level was decreased obviously（ P〈 0.05） when compared with baseline. Complete virological response rate at 48^th week was significantly associated with HBV DNA level at 4^th week. Conclusions Entecavir is effective and safe for patients with CHB. Virus load at 4thweek is a good predictor of complete virological response rate at 48^th week.